Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

818

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

818 results for “atrophy”

Learn how ShareScore rates datasets ↗
zenodo44/100

Atrophy Pattern Maps of Frontotemporal Dementia variants (bvFTD, svPPA, pnfaPPA)

<p>The files contain voxel-wise t-statistics maps contrasting deformation based morphometry (DBM) measurements of frontotemporal dementia (FTD) patients, divided according to subtype diagnosis, against matched normal controls.</p> <p>BV = behavioral-variant Frontotemporal Dementia</p> <p>SV = semantic-variant Primary Progressive Aphasia</p> <p>PNFA = non-fluent-variant Primary Progressive Aphasia</p> <p>&nbsp;</p> <p>FTD map is based on NIFD data, available at: https://memory.ucsf.edu/research/studies/nifd</p> <p>For more information regarding the participants and method details, see:</p> <p>Dadar, Mahsa, et al. "White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia."&nbsp;<em>Neurobiology of aging</em> 111 (2022): 54-63.</p> <p>Metz, Amelie, et al. "Brain Atrophy and White Matter Hyperintensities in Frontotemporal Dementia Variants and their Impact on Cognition" [Conference presentation] CCNA 2024 Partners Forum and Science Days (2024, March 19-21).</p>

opencc-by-4.0Dec 2023View details →
zenodo44/100

Atrophy Pattern Maps of Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, and Frontotemporal Dementia

<p>The files contain voxel-wise t-statistics maps contrasting deformation based morphometry (DBM) measurements of Alzheimer&#39;s disease (AD), Parkinson&#39;s disease (PD), mild cognitive impairment (MCI), and fronto-temporal dementia (FTD) patients against matched normal controls.</p> <p>AD and MCI maps are based on ADNI data, available at:</p> <p>PD map is based on PPMI data, available at:</p> <p>FTD map is based on NIFD data, available at:</p> <p>For more information regarding the participants and method details, see:</p> <p>Dadar, Mahsa, et al. &quot;White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer&#39;s disease and frontotemporal dementia.&quot; <em>Neurobiology of aging</em> 111 (2022): 54-63.</p>

opencc-by-4.0Dec 2022View details →
zenodo40/100

First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy

<p>Data from the paper: First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy, Nature Medicine 2024</p>

opencc-by-4.0Nov 2024View details →
zenodo40/100

Dataset related to article "SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples"

<p>mice survival after treatment with anti-miR-181a-5p; mice weight after treatment with anti-miR-324-5p</p>

opencc-by-4.0Jan 2022View details →
zenodo40/100

dataset relate to article "Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen"

<p>Excel file with raw data of the INQoL scale scores for each domain, for each patient, before and after nusinersen treatment</p>

opencc-by-4.0Feb 2023View details →
ClinicalTrials.gov40/100

An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)

ClinicalTrials.gov study NCT02268552. IPD Sharing: UNDECIDED. Countries: 7. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov40/100

Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

ClinicalTrials.gov study NCT03306277. IPD Sharing: YES. Countries: 1. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies

ClinicalTrials.gov study NCT03837184. IPD Sharing: YES. Countries: 3. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

ClinicalTrials.gov study NCT05089656. IPD Sharing: YES. Countries: 13. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)

ClinicalTrials.gov study NCT04851873. IPD Sharing: YES. Countries: 9. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

ClinicalTrials.gov study NCT04431713. IPD Sharing: NO. Countries: 1. Publications: 32.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov40/100

Expiratory Muscle Strength Training and Phonation Resistance Training Exercises For Elderly Patients With Vocal Fold Atrophy

ClinicalTrials.gov study NCT03696576. IPD Sharing: YES. Countries: 1. Publications: 33.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2

ClinicalTrials.gov study NCT03505099. IPD Sharing: YES. Countries: 6. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Spinal Cord Stimulation in Spinal Muscular Atrophy

ClinicalTrials.gov study NCT05430113. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

ClinicalTrials.gov study NCT03461289. IPD Sharing: YES. Countries: 4. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Futility Trial of Sirolimus in Multiple System Atrophy

ClinicalTrials.gov study NCT03589976. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
zenodo36/100

Measurement of Beta and Gamma Peripapillary Atrophy with Spectral Domain Optical Coherence Tomography

<p>Brief demonstration of the method used to measure beta and gamma peripapillary atrophy.</p>

opencc-by-sa-4.0Aug 2015View details →
zenodo36/100

Raw data for SELDI-TOF high range from article: Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis

<p>Raw normalised data from SELDI-TOF at high range following Expression Difference Mapping (ProteinChip Data Manager. Bio-Rad). Columns contain sample name, sample group (corresponds to longitudinal measurements for each patients at 1,3,4 and 5), peak number (all peaks detected at high&nbsp;range at each time point), peak intensity and mass/charge ratio.</p>

opencc-by-4.0Oct 2016View details →
zenodo36/100

Tumor-induced alterations in single-nucleus transcriptome of atrophying muscles

<h3><strong>Experimental Design</strong></h3> <p>Syngeneic C57BL/6 mice injected with Lewis Lung Carcinoma (LLC) cells were sacrificed 16 days after tumor inoculation while they experienced moderate cachexia and loss of muscle mass and function. We investigated single-nucleus transcriptomes of the tibialis anterior (TA) muscle from tumor-bearing mice and their non-tumor-bearing controls.</p> <h3><strong>Protocols</strong></h3> <p>Mice were housed at 22&deg;C and under 50% humidity with 12 hours of light and 12 hours of dark cycles (07:00 &ndash; 19:00) and given ad libitum access to a standard rodent chow diet and water in Koc University Animal Research Facility in accordance with institutional policies and animal care ethics guidelines.</p> <p>8-12 weeks old male mice with C57BL/6 background and Lewis lung carcinoma (LLC) cells were used for tumor inoculation. LLC cells were cultured in DMEM (Sigma, no. 5796) with 10% fetal bovine serum (FBS) and penicillin/streptomycin (Invitrogen). 5 million LLC cells were injected subcutaneously over the flank while control mice received PBS only. Muscle tissues were harvested at 16 days after LLC inoculation.</p> <p>TA muscle samples dissected from 6 mice in each group were combined and processed together. Samples were chopped with dissection scissors and placed into a lysis buffer containing 10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2, and 0.1% NP40 in nuclease-free water. Samples were homogenized using a douncer and filtered with 70 &micro;m and 40 &micro;m cell strainer. After centrifugation for 5 min at 500 g at 4 &deg;C, supernatant was discarded and nuclei were resuspended and stained with DAPI and subjected to fluorescence activated cell sorting.</p> <p>10X Genomics applications were used following the manufacturer&rsquo;s guidelines (Chromium Next GEM Single Cell 3ʹ Reagent Kits) to prepare the libraries, which were sequenced using the Illumina HiSeq X system.</p> <h3><strong>Data</strong></h3> <p>Sequencing data was first analyzed and filtered using Cell Ranger (v7.0) Single-Cell Software Suite provided by 10X Genomics. Data was counted and mapped with cellranger count function with --include-introns option for pre-mRNAs (mm10).</p> <p>Further analysis was performed using Seurat (v4.3.0) R (v4.2.2) package on R Studio (v2022.12.0), which filters nuclei, normalizes expression data, and carries out principal component analysis for clustering and Uniform Manifold Approximation and Projection (UMAP) visualization.</p> <h3><strong>Code</strong></h3> <p>You can see the code in R script file.</p>

opencc-by-4.0Apr 2024View details →
zenodo36/100

Search strategies for new born screening for spinal muscular atrophy (SMA)

<p>The dataset includes the complete, reproducible search strategies for all literature databases searched during this project.&nbsp;</p>

opencc-by-4.0Feb 2023View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record